A Prospective Comparison of Alcon LADARVision Wavefront-guided LASIK Enhancement and Conventional LASIK Enhancement for the Correction of Residual Refractive Errors Following LASIK Procedures
This study has been completed.
Sponsor:
Walter Reed Army Medical Center
Information provided by:
Walter Reed Army Medical Center
ClinicalTrials.gov Identifier:
NCT00413881
First received: December 19, 2006
Last updated: January 13, 2010
Last verified: March 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to conduct a prospective clinical trial to compare conventional and WFG LASIK for enhancements on post-LASIK patients. Differences in safety, efficacy, visual quality, and refractive stability will also be compared during this study.
| Condition | Intervention |
|---|---|
|
Refractive Errors |
Procedure: WAVEFRONT- GUIDED LASIK ENHANCEMENT Procedure: CONVENTIONAL LASIK ENHANCEMENT |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Prospective Comparison of Alcon LADARVision Wavefront-guided LASIK Enhancement and Conventional LASIK Enhancement for the Correction of Residual Refractive Errors Following LASIK Procedures |
Resource links provided by NLM:
MedlinePlus related topics:
Refractive Errors
Drug Information available for:
Dipivefrin hydrochloride
U.S. FDA Resources
Further study details as provided by Walter Reed Army Medical Center:
Primary Outcome Measures:
- 1.Safety 2. Efficacy 3. Refractive stability [ Time Frame: one year after enhancement ]
| Estimated Enrollment: | 50 |
| Study Start Date: | July 2004 |
| Study Completion Date: | March 2008 |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 2
Conventional LASIK Enhancement
|
Procedure: CONVENTIONAL LASIK ENHANCEMENT
Laser treatment to correct residual refractive error left over from initial LASIK correction using LADARvision 4000 excimer laser system.
|
|
Experimental: 1
Wavefront guided LASIK Enhancement
|
Procedure: WAVEFRONT- GUIDED LASIK ENHANCEMENT
Laser treatment to correct residual refractive error left over from initial LASIK correction using wavefront guided LADARvision 4000 excimer laser system
|
Eligibility| Ages Eligible for Study: | 21 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Male or female, of any race, and at least 21 years old at the time of the preoperative exam, and have signed an informed consent. The lower age limit of 21 years is intended to ensure documentation of refractive stability.
- At least 6 months from original LASIK surgery.
- Stable refraction with more than 0.75D of spherical equivalent from the desired correction and have less than 1.50D of cylinder in the manifest refraction.
- Both eyes must be within 1.00D spherical equivalent of each other on the manifest refraction test.
- The eye to be treated with wavefront-guided enhancement must have at least a 9.5mm flap.
- Manifest refraction and LADARWave™ refractions must be within 1.00D.
- At least 3 lines potential improvement in UCVA.
- BSCVA of 20/20 or better.
- Good corneal flap and interface.
- Adequate corneal thickness for surgery (residual stromal bed > 280 microns).
- Able and willing to give informed consent.
- Located in the greater Washington DC area for a 12-month period.
- Access to transportation to meet follow-up requirements.
Exclusion Criteria:
- Female subjects who are pregnant, breast-feeding or intend to become pregnant during the study. Pregnancy will be ruled out with a urine pregnancy test.
- Concurrent topical or systemic medications that may impair healing, including corticosteroids, antimetabolites, isotretinoin, amiodarone hydrochloride and/ or sumatripin, as determined by history.
- Medical condition(s), which, in the judgement of the investigator, may impair healing, including but not limited to: collagen vascular disease, autoimmune disease, immunodeficiency diseases, and ocular herpes zoster or simplex (As determined by history).
- Active ophthalmic disease, neovascularization of the cornea within 1mm of the intended ablation zone, or clinically significant lens opacity.
- Evidence of glaucoma or an intraocular pressure greater than 22mm Hg at baseline.
- Evidence of keratoconus, corneal irregularity, or abnormal videokeratography in either eye.
- Flap irregularity(striae, interface debris, scarring, or epithelium).
- Calculated residual stroma bed less than 280.
- Stable refraction with less than 0.75D of spherical equivalent from the desired correction and more than 1.5D of cylinder in the manifest refraction.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00413881
Locations
| United States, District of Columbia | |
| Walter Reed Army Medical Center, Center For Refractive Surgery | |
| Washington, District of Columbia, United States, 20307 | |
Sponsors and Collaborators
Walter Reed Army Medical Center
Investigators
| Principal Investigator: | RICHARD STUTZMAN, MD | Walter Reed Army Medical Center |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00413881 History of Changes |
| Other Study ID Numbers: | WRAMC WU # 04-23011 |
| Study First Received: | December 19, 2006 |
| Last Updated: | January 13, 2010 |
| Health Authority: | United States: Federal Government |
Keywords provided by Walter Reed Army Medical Center:
|
Residual refractive error left over from initial LASIK correction. Higher Order aberrations measured using a wavefront analyzer. |
Additional relevant MeSH terms:
|
Refractive Errors Eye Diseases |
ClinicalTrials.gov processed this record on May 21, 2013